Firat Ozcan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Firat Ozcan has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Serkan Cay
Division of Arrhythmia and Electrophysiology, Department of Cardiology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
8 shared publications - Ozcan Ozeke
Department of Cardiology University of Health Sciences, Ankara Bilkent City Hospital Ankara Turkiye
7 shared publications - Dursun Aras
Department of Cardiology, Istanbul Medipol University, Istanbul 34815, Türkiye
6 shared publications - Serkan Topaloglu
Department of Cardiology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
6 shared publications - Ahmet Korkmaz
Cardiology Department Ankara Bilkent City Hospital Ankara Turkey
4 shared publications - Elif Hande Ozcan Cetin
Cardiology Department Ankara Bilkent City Hospital Ankara Turkey
3 shared publications
Latest Publications
- 15 May 2026
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 12 (8) , 2051-2055
An Algorithmic Pitfall Causing Pacing-Induced Ventricular Fibrillation
- 15 May 2026
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 12 (8) , 2051-2055
An Algorithmic Pitfall Causing Pacing-Induced Ventricular Fibrillation
- 3 March 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (5) , 952-960
The Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence and Long‐Term Clinical Outcomes in HFrEF Patients Undergoing Cryoballoon Ablation: A New Frontier Beyond Diabetes and Heart Failure
Background: Atrial fibrillation (AF) recurrence remains a significant challenge in heart failure with reduced ejection fraction (HFrEF) patients undergoing cryoballoon ablation (CBA). Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) have demonstrated cardiovascular benefits, including antiarrhythmic effects. This study assesses the impact of SGLT2i on AF recurrence and clinical outcomes in HFrEF patients undergoing CBA. Methods: This retrospective cohort study was conducted on 246 HFrEF patients (LVEF < 40%) undergoing CBA between January 2022 and June 2024. Patients were categorized into two groups: SGLT2i users ( n = 71) and nonusers ( n = 175). The primary endpoint was AF recurrence (> 30 s post‐blanking period). Secondary endpoints included all‐cause mortality and heart failure (HF)‐related hospitalizations. Results: The median follow‐up period was 347 days. AF recurrence was lower in the SGLT2i group (25.4% vs. 39.4%, p = 0.036). Kaplan–Meier analysis demonstrated higher recurrence‐free survival in SGLT2i users (74.6% vs. 60.6%, log‐rank p < 0.001). Cox regression confirmed SGLT2i as an independent predictor of reduced AF recurrence (HR: 0.546, 95% CI: 0.262–0.874, p = 0.011). Mortality (9.9% vs. 14.9%, p = 0.039) and HF hospitalizations (16.9% vs. 23.4%, p = 0.014) were also significantly lower in SGLT2i users. Conclusion: SGLT2i use was independently associated with lower AF recurrence, mortality, and HF‐related hospitalizations in HFrEF patients undergoing CBA. These findings highlight the potential of SGLT2i as adjunctive therapy for AF management, necessitating further prospective studies to validate these results and optimize treatment strategies.
- 3 March 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (5) , 952-960
The Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence and Long‐Term Clinical Outcomes in HFrEF Patients Undergoing Cryoballoon Ablation: A New Frontier Beyond Diabetes and Heart Failure
Background: Atrial fibrillation (AF) recurrence remains a significant challenge in heart failure with reduced ejection fraction (HFrEF) patients undergoing cryoballoon ablation (CBA). Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) have demonstrated cardiovascular benefits, including antiarrhythmic effects. This study assesses the impact of SGLT2i on AF recurrence and clinical outcomes in HFrEF patients undergoing CBA. Methods: This retrospective cohort study was conducted on 246 HFrEF patients (LVEF < 40%) undergoing CBA between January 2022 and June 2024. Patients were categorized into two groups: SGLT2i users ( n = 71) and nonusers ( n = 175). The primary endpoint was AF recurrence (> 30 s post‐blanking period). Secondary endpoints included all‐cause mortality and heart failure (HF)‐related hospitalizations. Results: The median follow‐up period was 347 days. AF recurrence was lower in the SGLT2i group (25.4% vs. 39.4%, p = 0.036). Kaplan–Meier analysis demonstrated higher recurrence‐free survival in SGLT2i users (74.6% vs. 60.6%, log‐rank p < 0.001). Cox regression confirmed SGLT2i as an independent predictor of reduced AF recurrence (HR: 0.546, 95% CI: 0.262–0.874, p = 0.011). Mortality (9.9% vs. 14.9%, p = 0.039) and HF hospitalizations (16.9% vs. 23.4%, p = 0.014) were also significantly lower in SGLT2i users. Conclusion: SGLT2i use was independently associated with lower AF recurrence, mortality, and HF‐related hospitalizations in HFrEF patients undergoing CBA. These findings highlight the potential of SGLT2i as adjunctive therapy for AF management, necessitating further prospective studies to validate these results and optimize treatment strategies.
- 1 January 2023
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 17 (2) , 101-109
Effectiveness of the Systemic Immune Inflammation Index to Predict Atrial Fibrillation Recurrence After Cryoablation
Background: We aimed to investigate the predictive role of systemic immune inflammation index (SII) on atrial fibrillation (AF) recurrence following cryoballoon-based AF ablation. Materials & metho...
- 1 January 2023
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 17 (2) , 101-109
Effectiveness of the Systemic Immune Inflammation Index to Predict Atrial Fibrillation Recurrence After Cryoablation
Background: We aimed to investigate the predictive role of systemic immune inflammation index (SII) on atrial fibrillation (AF) recurrence following cryoballoon-based AF ablation. Materials & metho...
- Open Access
- 30 November 2020
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 23 (2) , 324
Left atrial or left atrial appendage thrombus as a cardiac source of embolus: that is the question or Faustian bargain for left atrial appendage closure?
- 30 November 2020
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 23 (2) , 324
Open AccessLeft atrial or left atrial appendage thrombus as a cardiac source of embolus: that is the question or Faustian bargain for left atrial appendage closure?
- 17 November 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (1) , 148-150
Change in the atrial activation timing and sequence during narrow QRS tachycardia: What is the mechanism?
- 17 November 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (1) , 148-150
Change in the atrial activation timing and sequence during narrow QRS tachycardia: What is the mechanism?
- 8 January 2020
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 14 (3) , 201-210
Relationship Between Apical Thrombus Formation and Blood Viscosity in Acute Anterior Myocardial Infarction Patients
Aim: This study sought to investigate the predictive value of whole blood viscosity (WBV) to identify high-risk patients who will develop an apical thrombus during the acute phase of anterior trans...
- 8 January 2020
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 14 (3) , 201-210
Relationship Between Apical Thrombus Formation and Blood Viscosity in Acute Anterior Myocardial Infarction Patients
Aim: This study sought to investigate the predictive value of whole blood viscosity (WBV) to identify high-risk patients who will develop an apical thrombus during the acute phase of anterior trans...
- Open Access
- 10 August 2017
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (1) , 217
To downgrade, or not to downgrade: that is the question
I have read with great interest the review paper entitled ‘Cardiac resynchronization therapy (CRT) device replacement considerations: upgrade or downgrade? A complex decision in the current clinical setting’ by Nakou et al. in the latest issue of the journal.1 They nicely summarized and commented on device selection at the time of replacement, considering patient’s history, demographics, clinical characteristics, and currently available scientific knowledge. Some important issues, however, should be mentioned; (i) Super response to cardiac resynchronization therapy (CRT) seems as a remission process, not a cure. Clinical and echocardiographic parameters have worsened when the CRT pacemaker was deactivated at the mid-term follow-up. Furthermore, hospitalizations for heart failure and appropriate device therapies have increased with deactivation.2 (ii) It is important to note that not all defibrillator therapies are...
- 10 August 2017
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (1) , 217
Open AccessTo downgrade, or not to downgrade: that is the question
I have read with great interest the review paper entitled ‘Cardiac resynchronization therapy (CRT) device replacement considerations: upgrade or downgrade? A complex decision in the current clinical setting’ by Nakou et al. in the latest issue of the journal.1 They nicely summarized and commented on device selection at the time of replacement, considering patient’s history, demographics, clinical characteristics, and currently available scientific knowledge. Some important issues, however, should be mentioned; (i) Super response to cardiac resynchronization therapy (CRT) seems as a remission process, not a cure. Clinical and echocardiographic parameters have worsened when the CRT pacemaker was deactivated at the mid-term follow-up. Furthermore, hospitalizations for heart failure and appropriate device therapies have increased with deactivation.2 (ii) It is important to note that not all defibrillator therapies are...
- 1 November 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 223, 217
Various routes and techniques for ablation of parahisian bypass tracts
- 1 November 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 223, 217
Various routes and techniques for ablation of parahisian bypass tracts
- Open Access
- 29 September 2014
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 19 (5)
Issue Information
- 29 September 2014
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 19 (5)
Open AccessIssue Information
- Open Access
- 1 January 2012
- Published by Turkish Society of Cardiology in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
- Vol. 40 (7) , 615-619
A case of acute coronary syndrome following the use of parenteral penicillin: Kounis syndrome
Kounis syndrome refers to the concurrence of acute coronary events and allergic or hypersensitivity reactions. In this report, we describe the case of a male patient, in whom acute ST-segment elevation and myocardial infarction developed immediately after injection of depot penicillin, and we discuss the Kounis syndrome. A 52-year-old male patient had chest pain, hypotension and ST-elevation on leads DI and aVL of electrocardiography 30 minutes after intramuscular penicillin injection due to cryptic tonsillitis. Kounis syndrome was considered as a possible diagnosis according to the presentation. Histamine and tryptase levels were not studied due to the delay on arrival to the emergency department. The patient promptly underwent coronary angiography, which revealed only diffuse plaques in all main coronary arteries without any obstructive lesion. We found only increased immunoglobulin (Ig) E, which is associated with the syndrome. With this report, we remind clinicians to consider Kounis syndrome in patients who are subjected to allergenic substances and demonstrate acute chest pain.
- 1 January 2012
- Published by Turkish Society of Cardiology in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
- Vol. 40 (7) , 615-619
Open AccessA case of acute coronary syndrome following the use of parenteral penicillin: Kounis syndrome
Kounis syndrome refers to the concurrence of acute coronary events and allergic or hypersensitivity reactions. In this report, we describe the case of a male patient, in whom acute ST-segment elevation and myocardial infarction developed immediately after injection of depot penicillin, and we discuss the Kounis syndrome. A 52-year-old male patient had chest pain, hypotension and ST-elevation on leads DI and aVL of electrocardiography 30 minutes after intramuscular penicillin injection due to cryptic tonsillitis. Kounis syndrome was considered as a possible diagnosis according to the presentation. Histamine and tryptase levels were not studied due to the delay on arrival to the emergency department. The patient promptly underwent coronary angiography, which revealed only diffuse plaques in all main coronary arteries without any obstructive lesion. We found only increased immunoglobulin (Ig) E, which is associated with the syndrome. With this report, we remind clinicians to consider Kounis syndrome in patients who are subjected to allergenic substances and demonstrate acute chest pain.